Orphan drug status granted to TOL101 for rejection of organ transplant

Tolera Therapeutics was granted orphan drug status by the FDA for its initial lead candidate, TOL101, for prophylaxis of acute rejection of solid organ transplantation. TOL101 is a biologic protein that is designed to safely and specifically target T cells, components of the immune system that play a key role in the rejection and failure of transplanted organs.

For more information call (877) 9-TOLERA or visit www.tolera.com.